12:00 AM
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vyvanse regulatory update

FDA accepted for review an sNDA from Shire for Vyvanse lisdexamfetamine dimesylate as maintenance treatment of ADHD in patients ages 6-17 years. The PDUFA date is April 29, 2013. Vyvanse is approved in the U.S....

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >